Spots Global Cancer Trial Database for neuroendocrine tumor
Every month we try and update this database with for neuroendocrine tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study | NCT01902238 | Efficacy Safety Feasibility | EUS-guided etha... | 18 Years - | Asan Medical Center | |
| DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor | NCT03143946 | Neuroendocrine ... | Vitamin supplem... Diet advice | 18 Years - | University Medical Center Groningen | |
| A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | NCT01476592 | Neuroendocrine ... | Resveratrol | 18 Years - | University of Wisconsin, Madison | |
| Surgical Intervention and the NETest | NCT03012789 | Neuroendocrine ... Gastroenteropan... | Surgery | 18 Years - | Wren Laboratories LLC | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor | NCT05749289 | Neuroendocrine ... | Al18F-octreotid... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Optimal Feeding for NET Patients | NCT02481804 | Neuroendocrine ... | Dietary interve... Standard treatm... | 18 Years - 90 Years | University Medical Center Groningen | |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | NCT05069220 | Neuroendocrine ... Neuroblastoma Pheochromocytom... Paraganglioma | 18F-MFBG 68Ga-Dotatate | 1 Year - 80 Years | Peking Union Medical College Hospital | |
| Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | NCT03352934 | Cancer | Avelumab | 18 Years - | Johannes Gutenberg University Mainz | |
| Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study | NCT01849523 | Distress Quality of Life Neuroendocrine ... | Web-based infor... | 18 Years - | University Medical Center Groningen | |
| Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | NCT01099540 | Neuroendocrine ... | Pazopanib | 18 Years - | Samsung Medical Center | |
| Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor | NCT05749289 | Neuroendocrine ... | Al18F-octreotid... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | NCT04400474 | Neuroendocrine ... Anaplastic Thyr... Adenocarcinoma Pheochromocytom... Paraganglioma | Cabozantinib 40... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | NCT00171873 | Neuroendocrine ... | Octreotide LAR ... Placebo | 18 Years - | Philipps University Marburg Medical Center | |
| Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | NCT01524783 | Advanced NET of... Advanced NET of... Neuroendocrine ... | Everolimus Placebo Best suportive ... | 18 Years - | Novartis | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | NCT00363051 | Islet Cell Carc... Neuroendocrine ... Neuroendocrine ... Pancreatic Neop... | Everolimus 10 m... Octreotide Depo... | 18 Years - | Novartis | |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | NCT00569127 | Colorectal Neur... Gastric Neuroen... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Bevacizumab Laboratory Biom... Octreotide Acet... Recombinant Int... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | NCT00227617 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... Neuroendocrine ... | bevacizumab 5-fluorouracil leucovorin oxaliplatin | 18 Years - | University of California, San Francisco | |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | NCT00569127 | Colorectal Neur... Gastric Neuroen... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Bevacizumab Laboratory Biom... Octreotide Acet... Recombinant Int... | - | National Cancer Institute (NCI) | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study | NCT02685631 | Localized Non-R... | Yttrium-90 Resi... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor | NCT03143946 | Neuroendocrine ... | Vitamin supplem... Diet advice | 18 Years - | University Medical Center Groningen | |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | NCT01024387 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | AMG 479 | 18 Years - | Dana-Farber Cancer Institute | |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients | NCT05701241 | Gastroenteropan... | Somatostatin an... | 18 Years - | University Hospital, Antwerp | |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | NCT04373564 | Motor Function Cognitive Funct... Contrast Media | Motor Tests Cognitive Tests Unenhanced-MRI ... Gadolinium Meas... Gadoxetate diso... Gadobenate dime... Gadodiamide Gadoterate megl... Gadobutrol Gadoteridol | 18 Years - 64 Years | Guerbet | |
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| A Study of XmAb®18087 in Subjects With NET and GIST | NCT03411915 | Neuroendocrine ... Gastrointestina... | XmAb18087 | 12 Years - | Xencor, Inc. | |
| Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors | NCT00569738 | Neuroendocrine ... | PET scan with G... | 18 Years - | Hadassah Medical Organization | |
| Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) | NCT01201096 | Liver Metastasis Neuroendocrine ... | 177Lutetium Liver transplan... | 18 Years - 60 Years | University of Jena | |
| Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs | NCT04696042 | Neuroendocrine ... | Lanreotide auto... | 19 Years - | Asan Medical Center | |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome | NCT00774930 | Carcinoid Syndr... | Lanreotide Placebo | 18 Years - | Ipsen | |
| Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery. | NCT04735198 | Midgut Carcinoi... Biliary Stones | Primary tumor s... Primary tumor s... | 18 Years - | Hospital Universitari de Bellvitge | |
| Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | NCT02030184 | Small Cell Lung... Neuroendocrine ... Large Cell Neur... | Rhenium Re 188-... | 18 Years - | University of Maryland, Baltimore | |
| Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery. | NCT04735198 | Midgut Carcinoi... Biliary Stones | Primary tumor s... Primary tumor s... | 18 Years - | Hospital Universitari de Bellvitge | |
| Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) | NCT01201096 | Liver Metastasis Neuroendocrine ... | 177Lutetium Liver transplan... | 18 Years - 60 Years | University of Jena | |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NCT04907643 | Cancer Pain Visceral Pain Gastrointestina... Cancer of Gastr... Small Intestine... Pancreas Cancer Liver Cancer Colon Cancer Biliary Tract C... Stomach Cancer Rectum Cancer Peritoneal Canc... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Small Intestine... Small Intestine... Small Intestine... Pancreas Cancer... Pancreas Cancer... Pancreas Cancer... Pancreas Cancer... Liver Cancer St... Liver Cancer St... Liver Cancer St... Liver Cancer St... Colon Cancer St... Colon Cancer St... Stomach Cancer ... Stomach Cancer ... Stomach Cancer ... Rectum Cancer, ... Gastrointestina... Anal Cancer Anal Cancer Sta... Anal Cancer Sta... Anal Cancer Rec... Anal Cancer Met... Anal Cancer, St... Anal Cancer, St... Appendix Cancer Ampullary Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Carcinoid Tumor Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Large Intestine... Esophagus Cance... Esophagus Cance... Esophagus Cance... Esophagus Cance... Gallbladder Can... Gallbladder Can... Gallbladder Can... Gastric (Stomac... Neuroendocrine ... Peritoneum Canc... Rectal Cancer Esophagus Cance... Esophagus Cance... Gallbladder Can... Gallbladder Can... Bile Duct Cance... Bile Duct Cance... | PICO G2 4k | 18 Years - 99 Years | Cedars-Sinai Medical Center | |
| A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | NCT01476592 | Neuroendocrine ... | Resveratrol | 18 Years - | University of Wisconsin, Madison | |
| Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency | NCT04073017 | Neuroendocrine ... Carcinoid Syndr... | Enterade® Functional Asse... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | NCT01099540 | Neuroendocrine ... | Pazopanib | 18 Years - | Samsung Medical Center | |
| 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. | NCT02088645 | Thyroid Cancer,... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-PP-F11N | 18 Years - | University Hospital, Basel, Switzerland | |
| Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study | NCT01849523 | Distress Quality of Life Neuroendocrine ... | Web-based infor... | 18 Years - | University Medical Center Groningen | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00131911 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Neuroendocrine ... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | sorafenib tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences | NCT03948841 | Neuroendocrine ... | magnetic resona... | 18 Years - 90 Years | CHU de Reims | |
| Evaluation of Study Experiences of Neuroendocrine Tumor Patients | NCT05967481 | Neuroendocrine ... | 18 Years - | Power Life Sciences Inc. | ||
| 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer | NCT01396382 | Neuroendocrine ... | 68Ga-DOTATATE P... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) | NCT05816720 | Neuroendocrine ... | Lutetium-177 DO... | 18 Years - | Novartis | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors | NCT00569738 | Neuroendocrine ... | PET scan with G... | 18 Years - | Hadassah Medical Organization | |
| Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor | NCT02472678 | Neuroendocrine ... | Web-based tailo... Standard care | 18 Years - 90 Years | University Medical Center Groningen | |
| Optimal Feeding for NET Patients | NCT02481804 | Neuroendocrine ... | Dietary interve... Standard treatm... | 18 Years - 90 Years | University Medical Center Groningen | |
| Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases | NCT03590119 | Neuroendocrine ... Liver Metastase... | Lutetium Lu 177... | 18 Years - | UMC Utrecht | |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | NCT00458952 | Pheochromocytom... Paraganglioma | Ultratrace Iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors | NCT01456078 | Neuroendocrine ... Liver Metastase... | 177Lu-DOTA-TATE | 18 Years - 70 Years | Lund University Hospital | |
| Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours | NCT01448083 | Neuroendocrine ... | Standard of car... | 18 Years - | Nuclear Medicine Consultants, Inc. | |
| Combination Targeted Radiotherapy in Neuroendocrine Tumors | NCT01099228 | Neuroendocrine ... | 131-I MIBG and ... 131-I MIBG and ... | 18 Years - | University of Iowa | |
| Nutrition in Gastroenteropancreatic Neuroendocrine Tumor | NCT04986085 | Gastroenteropan... | 18 Years - 80 Years | Grupo Espanol de Tumores Neuroendocrinos | ||
| Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours | NCT01448083 | Neuroendocrine ... | Standard of car... | 18 Years - | Nuclear Medicine Consultants, Inc. | |
| Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | NCT03352934 | Cancer | Avelumab | 18 Years - | Johannes Gutenberg University Mainz | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NCT04907643 | Cancer Pain Visceral Pain Gastrointestina... Cancer of Gastr... Small Intestine... Pancreas Cancer Liver Cancer Colon Cancer Biliary Tract C... Stomach Cancer Rectum Cancer Peritoneal Canc... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Small Intestine... Small Intestine... Small Intestine... Pancreas Cancer... Pancreas Cancer... Pancreas Cancer... Pancreas Cancer... Liver Cancer St... Liver Cancer St... Liver Cancer St... Liver Cancer St... Colon Cancer St... Colon Cancer St... Stomach Cancer ... Stomach Cancer ... Stomach Cancer ... Rectum Cancer, ... Gastrointestina... Anal Cancer Anal Cancer Sta... Anal Cancer Sta... Anal Cancer Rec... Anal Cancer Met... Anal Cancer, St... Anal Cancer, St... Appendix Cancer Ampullary Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Bile Duct Cance... Carcinoid Tumor Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Carcinoid Tumor... Large Intestine... Esophagus Cance... Esophagus Cance... Esophagus Cance... Esophagus Cance... Gallbladder Can... Gallbladder Can... Gallbladder Can... Gastric (Stomac... Neuroendocrine ... Peritoneum Canc... Rectal Cancer Esophagus Cance... Esophagus Cance... Gallbladder Can... Gallbladder Can... Bile Duct Cance... Bile Duct Cance... | PICO G2 4k | 18 Years - 99 Years | Cedars-Sinai Medical Center | |
| Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study | NCT02147106 | Neuroendocrine ... | Videoconsultati... | 18 Years - | University Medical Center Groningen | |
| Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | NCT02063958 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies | NCT02177773 | Neuroendocrine ... Paraganglioma Carcinoid Tumor... Neuroblastoma | Computed Tomogr... Gallium Ga 68-E... Magnetic Resona... Positron Emissi... | 2 Years - | University of California, San Francisco | |
| Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs | NCT04696042 | Neuroendocrine ... | Lanreotide auto... | 19 Years - | Asan Medical Center | |
| Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study | NCT02147106 | Neuroendocrine ... | Videoconsultati... | 18 Years - | University Medical Center Groningen | |
| Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | NCT02063958 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor | NCT03143946 | Neuroendocrine ... | Vitamin supplem... Diet advice | 18 Years - | University Medical Center Groningen | |
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00942682 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | Sorafenib RAD001 | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
